NRX Pharmaceuticals, Inc.
NRXPFigures shown here come from public SEC filings. Dates beside each section show the available history.
How NRX Pharmaceuticals, Inc. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 8 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Feb 17, 2026. The latest institutional report shown is dated Mar 31, 2024; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| MORGAN STANLEY | 2024-03-31 | 43,948 | Not shown | SEC filing |
| JPMORGAN CHASE & CO | 2024-03-31 | 492 | Not shown | SEC filing |
| MORGAN STANLEY | 2024-03-31 | 43,948 | Not shown | SEC filing |
| Royal Bank of Canada | 2024-03-31 | 125 | Not shown | SEC filing |
| MORGAN STANLEY | 2023-12-31 | 44,334 | Not shown | SEC filing |
| JPMORGAN CHASE & CO | 2023-12-31 | 16,812 | Not shown | SEC filing |
- Each value is checked against NRX Pharmaceuticals, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 6 rows: no share price from within three months of their report dates is on file, so they could not be checked.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- JPMORGAN CHASE & CO: 16,812 shares reported 2023-12-31; 492 shares reported 2024-03-31.
1 filer has only one report here.
Independent insiders buying near the same time
- 2023-08-30–2023-08-30: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
- 2022-12-16–2022-12-16: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2024-12-17 | Javitt Jonathan C · Chairman and Chief Scientist | Common Stock | P — Open market or private purchase | +40,000 | 1.17 | SEC filing |
| 2023-08-30 | Gorovitz Aaron · Director | Common Stock, par value $0.001 per share | P — Open market or private purchase | +35,000 | 0.32 | SEC filing |
| 2023-08-30 | Hurvitz Chaim · Director | Common Stock, par value $0.001 per share | P — Open market or private purchase | +70,000 | 0.29 | SEC filing |
| 2023-08-23 | Javitt Jonathan C · Chief Scientist | Common Stock | P — Open market or private purchase | +100,000 | 0.33 | SEC filing |
| 2023-08-22 | Javitt Jonathan C · Chief Scientist | Common Stock | P — Open market or private purchase | +200,000 | 0.32 | SEC filing |
| 2022-12-16 | VAN VOORHEES SETH · CHIEF FINANCIAL OFFICER | Common Stock, par value $0.001 per share | P — Open market or private purchase | +30,000 | 1.10 | SEC filing |
| 2022-12-16 | Willard Stephen H · CHIEF EXECUTIVE OFFICER | Common Stock, par value $0.001 per share | P — Open market or private purchase | +50,000 | 1.17 | SEC filing |
| 2022-12-07 | Javitt Jonathan C · Director, 10% owner | Common Stock, par value $0.001 per share | S — Open market or private sale | −400,000 | 1.00 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-01-27 | Casper Joseph Michael · Chief Operating Officer | Stock Option (right to buy) | A — Grant, award, or other acquisition | +100,000 | SEC filing |
| 2025-04-09 | McBride Dennis · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +25,000 | SEC filing |
| 2025-04-09 | Javitt Jonathan C · Chairman and Chief Scientist | Stock Option (right to buy) | A — Grant, award, or other acquisition | +125,000 | SEC filing |
| 2025-04-09 | Flynn Patrick John · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +50,000 | SEC filing |
| 2025-04-09 | Hurvitz Chaim · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +25,000 | SEC filing |
| 2025-02-07 | ABRAMS MICHAEL S · Chief Financial Officer | Stock Option (right to buy) | A — Grant, award, or other acquisition | +50,000 | SEC filing |
| 2022-12-14 | Javitt Jonathan C · Director, 10% owner | Common Stock, par value $0.001 per share | G — Bona fide gift | −300,000 | SEC filing |
| 2022-10-21 | Glied Sharon · Director | Employee Stock Option | A — Grant, award, or other acquisition | +162,660 | SEC filing |
Showing 8 of 23 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2021-05-24 (amended) | BRAC Lending Group LLC · 10% owner | Common Stock | D — Disposition to the issuer | −869,565 | SEC filing |
| 2021-05-24 | ACKERMAN RICHARD · President & CEO | Common Stock | D — Disposition to the issuer | −5,435 | SEC filing |
Showing 2 of 2 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.